SUMITOMO PHARMA CO LTD
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- $1.8B
Clinical Trials
50
Trial Phases
4 Phases
Drug Approvals
17
Drug Approvals
Arotinolol Hydrochloride Tablets
- Product Name
- 阿尔马尔
- Approval Number
- 国药准字HJ20140677
- Approval Date
- Jun 7, 2023
Arotinolol Hydrochloride Tablets
- Product Name
- 阿尔马尔
- Approval Number
- 国药准字HJ20140676
- Approval Date
- Jun 7, 2023
Tandospirone Citrate Tablets
- Product Name
- 希德
- Approval Number
- 国药准字HJ20181227
- Approval Date
- Mar 20, 2023
Tandospirone Citrate Tablets
- Product Name
- 希德
- Approval Number
- 国药准字HJ20181228
- Approval Date
- Mar 20, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: fH1 2 ugBiological: fH1 8 ugBiological: PlaceboBiological: DSP-0546LP 5 ugBiological: DSP-0546LP 10 ugBiological: DSP-0546LP 2.5 ug
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Sumitomo Pharma Co. Ltd.
- Target Recruit Count
- 144
- Registration Number
- 2023-504378-39-00
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
- Conditions
- Parkinson's DiseaseLevodopa-induced Dyskinesia
- Interventions
- Drug: DSP-9632P 27.5 mgDrug: PlaceboDrug: DSP-9632P 82.5 mgDrug: DSP-9632P 55.0 mg
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05435729
- Locations
- 🇯🇵
Nippon Medical School Hospital, Bunkyo, Tokyo, Japan
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05359081
- Locations
- 🇯🇵
Hotei Hospital, Konan-shi, Aichi, Japan
🇯🇵Heart Care Clinic Omachi, Akita-shi, Akita, Japan
🇯🇵Seinan Hospital, Hachinohe-shi, Aomori, Japan
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT04825860
- Locations
- 🇨🇳
Beijing Anding Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University Sixth Hospital, Beijing, Beijing, China
🇨🇳The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT04325737
- Locations
- 🇯🇵
Shiranui Hospital, Omuta-shi, Fukuoka-Ken, Japan
🇯🇵Nishiurakai Keihan Hospital, Osaka-Fu, Moriguchi-shi, Japan
🇯🇵Mental Support SOYOKAZE Hospital, Ueda-shi, Nagano-Ken, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Poxel Enters Reorganization Proceedings as Clinical-Stage Biotech Faces Financial Restructuring
Poxel SA, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, has entered judicial reorganization proceedings following a court hearing on August 5, 2025.
Knight Therapeutics Acquires Sumitomo's Canadian Portfolio Including MYFEMBREE and ORGOVYX for C$25.4 Million
Knight Therapeutics has entered into exclusive licensing agreements with Sumitomo Pharma to commercialize MYFEMBREE, ORGOVYX, and vibegron in Canada for an upfront payment of C$25.4 million.
Poxel's PXL065 Shows Promise in Preclinical Hypertrophic Cardiomyopathy Study, Data to be Presented at ESC 2025
Poxel's PXL065, a deuterium-stabilized R-enantiomer of pioglitazone, demonstrated significant benefits in preventing pathological myocardial remodeling in a mouse model of hypertrophic cardiomyopathy.
Schizophrenia Clinical Trial Pipeline Boasts 60+ Drugs Under Development
• The schizophrenia treatment landscape is expanding with over 60 drugs in active development, driven by increased R&D and innovative therapies. • Key players like Sumitomo Pharma, Boehringer Ingelheim, and Reviva Pharmaceuticals are advancing novel antipsychotics and personalized medicine approaches. • Recent progress includes positive Phase III trial results for brilaroxazine and LY03020's IND approval in China, signaling potential new treatment options. • COBENFY, a first-in-class muscarinic agonist, received FDA approval, marking a significant advancement in schizophrenia treatment after 35 years.
FDA Accepts Sumitomo Pharma's sNDA for Vibegron in Men with OAB and BPH
The FDA has accepted Sumitomo Pharma's sNDA for vibegron (GEMTESA) to treat OAB symptoms in men receiving BPH pharmacological therapy.
Imeglimin's Impact on Glycemic Control and Erythrocytes in Type 2 Diabetes: INFINITY Study
The INFINITY study investigates imeglimin's effects on glycemic control markers and erythrocytes in type 2 diabetes patients over six months.